Biomark生物科技


Biomark团队通过科学的资源分配,严格遵守当地法律法规,以减少与项目相关的风险。


BioMark China大事记

  • 获得韩国光福农场产品除韩国地区全球代理权 - 2014.11
  • 获得韩国BEAUTEE COLLAGE公司产品中国地区代理权 - 2014.6
  • TOP SACHI (顶棘)品牌确立 - 2014.5
  • REPARO品牌官网上线 - 独立运营 - 2014.4
  • REPARO品牌确立 - 2013.11
  • 公司迁址新办公楼 - 2013.1
  • 荣获《高新技术企业》称号 - 2012.9

  • BioMark Tech大事记

  • 计划进行随机测试,建立标准 - later in 2014
  • Additional studies are underway to establish Proof of Concept on BioMark’s leading antibody based drug. Further IND planning activities are being planned post proof of concept completion
  • Started a Control Group III re-trial based on PK data from China. A new CTA from Health Canada and Ethics Board approval was obtained in October 2011 and the trial commenced in late November 2011 and completed late April 2012 at Saint Boniface in Manitoba. Reconfirmed prior PK tests in China. BioMark has obtained approval for phase III clinical trial from Health Canada and will be commencing the studies in December of 2012 at Cancer Care Manitoba.
  • BioMark has filed provisional patents for 2 novel antibody based therapeutic agents.
  • BioMark has filed a provisional patent in December 2012 for a new approach in detection using Raman IR systems with the University of Victoria.
  • BioMark has filed a provisional patent in December 2012 for the generation of small molecule antibody that will be used for development of IVD kits.
  • BioMark has begun studies in December 2012 with Manitoba Tumour Bank for SSAT gene expression studies.
  • New targeted imaging studies with the University of British Columbia, BC Pre-clinical Consortium and Triumph is underway with expected results early 2013.
  • Successfully identified 3 additional substrates into our patent portfolio beyond amantadine. This would provide potential avenue for use of new substrates – conduct cell line and xenograft models for drug screening application.
  • Established and generated our data on the presence of SSAT in 3 cancer cell lines based on a positive correlation of RT-qPCR of mRNA and functional SSAT activities to confirm the comparative non-specific as Northern-blot data.
  • 完成Km和Vmax新SSAT1基材
  • SSAT 1研究突破及SSAT 2更有针对的应用
  • 专利获得:完成单体克隆抗体的乙醇金刚烷胺并使之不具亲和力 - 2012年
  • 获得资助 - 美国国家研究院加拿大分部 - IRAP - 2010.4 ~ 2012
  • BioMark等4家加拿大公司入选加拿大政府商业化技术代表 - 美国旧金山硅谷 Genentech Centre

  • 更早期

  • 2008年2-3月 出席美国旧金山Biomarker研讨会。
  • 2007年2月 与韩国贸易投资振兴公社达成生物科技合作计划
  • 2007年2月 出席迪拜Arab健康研讨会
  • 2007年1月 加入香港美西玉山科技协会
  • 2006年12月 申请加入加拿大国际贸易全球化项目
  • 2006年11月 申请曼尼托巴省IRAP基金
  • 制定到中国进行临床试验和医药研发外包的规划
  • 2006年11月 完成了CIHR POP申请(应用)
  • 与河南省人民医院签署意向书
  • 访问中国抗癌协会,并商讨合作研究的机会
  • 2007年10月 参加北京召开的中国通路2008讨论会。
  • 2006年9月 与曼尼托巴大学Richardson研究中心功能食物和Nuetracueticals签署了交叉验证研究委托书。
  • 2006年9月 获得来自曼尼托巴大学IPM的补助金。
  • 邀请Innus GmbH代表团协商在欧洲开展研究和申请技术执照的可能性
  • 2006年8月 出席台北生物研讨会